Vitamin D in Prostate Cancer

Vitamins and Hormones

Volumn 100, Issue , 2016, Pages 321-355

  Ahn, Jungmi ^a   Park, Sulgi ^a   Zuniga, Baltazar ^a,b   Bera, Alakesh ^a   Song, Chung Seog ^a   Chatterjee, Bandana ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Androgen receptor; Growth inhibition VDR metabolism; Intracrine androgen metabolism; Metastatic castration resistant prostate cancer; Transcriptional regulation; Vitamin D; Vitamin D receptor

Indexed keywords

CALCITRIOL RECEPTOR; VITAMIN D;

HUMAN; MALE; METABOLISM; PROSTATIC NEOPLASMS;

HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 84949636775     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.vh.2015.10.012     Document Type: Chapter

References (112)

1. Ajibade A.A., Kirk J.S., Karasik E., Gillard B., Moser M.T., Johnson C.S., et al. Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer. PLoS One 2014, 9:e89555.
2. Albanes D., Mondul A.M., Yu K., Parisi D., Horst R.L., Virtamo J., et al. Serum 25-hydroxyvitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiology, Biomarkers and Prevention 2011, 20(9):1850-1860.
3. Aleksunes L.M., Klaassen C.D. Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARα-, and Nrf2-null mice. Drug Metabolism and Disposition 2012, 40:1366-1379.
4. Alimirah F., Vaishnav A., Mc Cormick M., Echchgadda I., Chatterjee B., Mehta R.G., et al. Functionality of unliganded VDR in breast cancer cells: Repressive action on CYP24 basal transcription. Molecular and Cellular Biochemistry 2010, 342:143-150.
5. Al Mutair A.N., Nasrat G.H., Russell D.W. Mutation of the CYP2R1 vitamin D 25-hydroxylase in a Saudi Arabian family with severe vitamin D deficiency. The Journal of Clinical Endocrinology and Metabolism 2012, 97:E2022-E2025.
6. Attia S., Elckhoff J., Wilding G., McNeel D., Blank J., Ahuja H., et al. Randomized double blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic androgen-independent prostate cancer. Clinical Cancer Research 2008, 14:2437-2443.
7. Babiker A.M., Al Gadi I., Al-Jurayyan N.A., Al Nemri A.M., Al Haboob A.A., Al Boukai A.A., et al. A novel pathogenic mutation of the CYP27B1 gene in a patient with vitamin D-dependent rickets type 1: A case report. BMC Research Notes 2014, 7:783.
8. Banach-Petrosky W., Jessen W.J., Ouyang X., Gao H., Rao J., Quinn J., et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Research 2007, 67:9089-9096.
9. Bao B.-Y., Hu Y.-C., Ting H.-J., Lee Y.-F. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 2004, 23:3350-3360.
10. Bao B.Y., Yeh S.D., Lee Y.F. 1α, 25 dihydroxy vitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006, 27:32-42.
11. Blutt S.E., McDonnell T.J., Polek T.C., Weigel N.L. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000, 138:1491-1497.
12. Boyle B.J., Zhao X.Y., Cohen P., Feldman D. Insulin-like growth factor binding protein3 mediates 1 alpha 25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. The Journal of Urology 2001, 165:1319-1324.
13. Campbell M.J., Elstner E., Holden S., Uskokovic M., Koeffler H.P. Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves induction of p21waf1, p27Kip1 and E-cadherin. Journal of Molecular Endocrinology 1997, 19:15-27.
14. Carlberg C. Genome-wide(overview) on the actions of vitamin D. Frontiers in Physiology 2014, 5:1-10. (article number: 167). 10.3389/fphys.2014.00167.
15. Carlberg C., Bendik I., Wyss A., Meier E., Sturzenbecker L.A., Grippo J.F., et al. Two nuclear signaling pathways for vitamin D. Nature 1993, 361:657-660.
16. Carlberg C., Campbell M.J. Vitamin D receptor signaling mechanisms: Integrated actions of a well-defined transcription factor. Steroids 2013, 78:127-136.
17. Chanakul A., Zhang M.Y.H., Louw A., Armbrecht H.J., Miller W.L., Portale A.A., et al. FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues. PLoS One 2013, 8(9):e72816.
18. Chen T.C. 25-Hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1) is a new class of tumor suppressor in the prostate. Anicancer Research 2008, 28(4A):2015-2017.
19. Chen T.C., Holick M.F. Vitamin D and prostate cancer prevention and treatment. TRENDS in Endocrinology and Metabolism 2003, 14:423-430.
20. Chen T.C., Sakai T., Yamamoto K., Kittaka A. The roles of cytochrome P450 enzymes in prostate cancer development and treatment. Anticancer Research 2012, 32:291-298.
21. Chung I., Han G., Seshadri M., Gillard B.M., Yu W.-d., Foster B.A., et al. Role of VDR in anti-proliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Research 2009, 69:967-975.
22. Costello L.C., Franklin R.B. Concept of citrate production and secretion by prostate 1. Metabolic relationships. Prostate 1991, 18:25-46.
23. Costello L.C., Franklin R.B. Concept of citrate production and secretion by prostate 2. Hormonal relationship in normal and neoplastic prostate. Prostate 1991, 19:181-205.
24. Datta M., Schwartz G.G. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: A critical review. The Oncologist 2012, 17(9):1171-1179.
25. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., et al. Abiraterone and increased survival in metastatic prostate cancer. The New England Journal of Medicine 2011, 364:1995-2005.
26. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nature Reviews. Cancer 2007, 7(9):684-700.
27. DeLuca H.F. History of the discovery of vitamin D and its active metabolites. BoneKEy Reports 2014, 3:1-8. (article number: 479). 10.1038/bonekey.2013.213.
28. DeMarzo A.M., Platz E.A., Sutcliffe S., Xu J., Grönberg H., Drake C.G., et al. Inflammation in prostate carcinogenesis. Nature Reviews. Cancer 2007, 7:256-269.
29. Doherty D., Dvorkin S.A., Rodriguez E.P., Thompson P.D. Vitamin D receptor agonist EB1089 is a potent regulator of prostatic intracrine metabolism. Prostate 2014, 74:273-285.
30. Evans R.M., Mangelsdorf D.J. Nuclear receptors, RXR, and the big bang. Cell 2014, 157:255-266.
31. Feldman D., Krishnan A.V., Swami S., Giovannucci E., Feldman B.J. The role of vitamin D in reducing cancer risk and progression. Nature Reviews. Cancer 2014, 14:342-357.
32. Feldman D., Zhao X.-Y., Krishnan A.V. Vitamin D and prostate cancer. Endocrinology 2000, 141(1):5-9.
33. Ferla S., Aboraia A.S., Brancale A., Pepper C.J., Zhu J., Ochalek J.T., et al. Small-molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): Synthesis and biological evaluation. Journal of Medicinal Chemistry 2014, 57:7702-7715.
34. Fujimura T., Takahashi S., Uno T., Kumagai J., Murata T., Takayama K., et al. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology 2009, 74:391-397.
35. Getzenberg R.H., Light B.W., Lapco P.E., Konety B.R., Nangia A.K., Acierno J.S., et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997, 50:999-1006.
36. Godoy A.S., Chung I., Montecinos V.P., Buttyan R., Johnson C.S., Smith G.J. Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate. American Journal of Physiology. Endocrinology and Metabolism 2013, 304:E1131-E1139.
37. Guzey M., Kitada S., Reed J.C. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Molecular Cancer Therapeutics 2002, 1:667-677.
38. 3 modulated gene expression patterns in human primary normal and cancer prostate cells. Journal of Cellular Biochemistry 2004, 93:271-285.
39. Harshman L.C., Wang X., Nakabayashi M., Xie W., Valenca L., Werner L., et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncology 2015, 1(4):495-504. 10.1001/jamaoncol.2015.0829.
40. 3: Genomic and non-genomic mechanisms. Best Practice & Research. Clinical Endocrinology & Metabolism 2011, 25:543-559.
41. Helsen C., Claessens F. Looking at nuclear receptors from a new angle. Molecular and Cellular Endocrinology 2014, 382:97-106.
42. Hendrickson W.K., Flavin R., Kasperzyk J.L., Fiorentino M., Fang F., Lis R., et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. Journal of Clinical Oncology 2011, 29:2378-2385.
43. Hershberger P.A., Yu W., Modzelewski R.A., Rueger R.M., Johnson C.S., Trump D.L. Calcitriol (1,25-Dihydroxycholecalci-ferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clinical Cancer Research 2001, 7:1043-1051.
44. Hollis B.W. Vitamin D in the prevention and treatment of cancer 2015.
45. Hsu J.Y., Feldman D., McNeal J.E., Peehl D.M. Reduced 1a-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Research 2001, 61:2852-2856.
46. Hu Y., Fu L. Targeting cancer stem cells: A new therapy to cure cancer patients. American Journal of Cancer Research 2012, 2:340-356.
47. Huang P., Chandra V., Rastinejad F. Structural overview of the nuclear receptor superfamily: Insights into physiology and therapeutics. Annual Review of Physiology 2010, 72:247-272.
48. Jamieson D., Holick M.F., Chen T.C. Regulation of 25-hydroxyvitamin D-1 alpha-hydroxylase by epidermal growth factor in prostate cells. The Journal of Steroid Biochemistry and Molecular Biology 2004, 89-90:127-130.
49. Kojima S., Mulholland D.J., Ettinger S., Fazli L., Nelson C.C., Gleave M.E. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate 2006, 66:971-986.
50. Krishnan A.V., Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annual Review of Pharmacology and Toxicology 2011, 51:311-336.
51. Krishnan A.V., Moreno J., Nonn L., Malloy P., Swami S., Peng L., et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 2007, 103:694-702.
52. Lau Y.K., Trump D.L., Johnson C. Interaction of vitamin D receptor and androgen receptor in human prostate cancer cell line. Journal of Clinical Oncology 2004, 22(14S). (2004 ASCO annual meeting proceedings (post-meeting edition); Abstract # 9550).
53. Leman E.S., Ariotti J.A., Dhir R., Getzenberg R.H. Vitamin D and androgen regulation of prostatic growth. Journal of Cellular Biochemistry 2003, 90:138-147.
54. Li J., Fleet J.C., Teegarden D. Activation of rapid signaling pathways does not contribute to 1alpha, 25-dihydroxy vitamin D3-induced growth inhibition of mouse prostate epithelial progenitor cells. Journal of Cellular Biochemistry 2009, 107:1031-1036.
55. Li H., Stampfer M.J., Hollis J.B.W., Mucci L.A., Gaziano J.M., Hunter D., et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Medicine 2007, 4(3):e103.
56. Luo W., Karpf A.R., Deeb K.K., Muindi J.R., Morrison C.D., Johnson C.S., et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Research 2010, 70:5953-5962.
57. Maguire O., Pollock C., Martin P., Owen A., Smyth T., Doherty D., et al. Regulation of CYP3A4 and CYP3A5 expression and modulation of intracrine metabolism of androgens in prostate cells by liganded vitamin D receptor. Molecular and Cellular Endocrinology 2012, 364:54-64.
58. Manson J.E., Bassuk S., et al. The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials 2012, 33:159-171.
59. Marchiani S., Bonaccorsi L., Ferruzzi P., Crescioli C., Muratori M., Adorini L., et al. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. Journal of Cancer Research and Clinical Oncology 2006, 132:408-416.
60. Marshall D., Savage S.J., Garrett-Mayer E., Keane T.E., Hollis B.W., Horst R.L. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. The Journal of Clinical Endocrinology and Metabolism 2012, 97:2315-2324.
61. Maund S.L., Barclay W.W., Hover L.D., Axanova L.S., Sui G., Hipp J.D., et al. Interleukin-1 alpha mediates the anti-proliferative effects of 1,25 dihydroxyvitamin D3 in prostate progenitor/stem cells. Cancer Research 2011, 71(15):5276-5286.
62. Medioni J., Deplanque G., Ferrero J.-M., Maurina T., Rodier J.-M., Raymond E., et al. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients. Clinical Cancer Research 2014, 20(17):4471-4477.
63. Meijsing S.H., Pufall M.A., So A.Y., Bates D.L., Chen L., Yamamoto K.R. DNA binding site sequence directs glucocorticoid structure and activity. Science 2009, 324:407-410.
64. Mitsiades N., Sung C.C., Schultz N., Danilla D.C., He B., Eedunuri V.K., et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Research 2012, 72:6142-6152.
65. Moffatt K.A., Johannes W.U., Hedlund T.E., Miller G.J. Growth inhibitory effects of 1α, 25-dihydroxyvitamin D3 are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Research 2001, 61:7122.
66. Mordan-McCombs S., Brown T., Wang W.L., Gaupel A.C., Welsh J., Tenniswood M. Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. The Journal of Steroid Biochemistry and Molecular Biology 2010, 121:368-371.
67. Moreno J., Krishnan A.V., Feldman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 2005, 97:31-36.
68. Moreno J., Krishnan A.V., Peehl D.M., Feldman D. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: Inhibition of the prostaglandin pathway. Anticancer Research 2006, 26:2525-2530.
69. Mostaghel E.A. Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Management and Research 2014, 6:39-51.
70. Mostaghel E.A., Nelson P.S. Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Practice & Research. Clinical Endocrinology & Metabolism 2008, 22:243-258.
71. Murthy S., Agoulnik I.U., Weigel N.L. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 2005, 64:362-372.
72. Oades G.M., Dredge K., Kirby R.S., Colston K.W. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU International 2002, 90:607-616.
73. Okamoto R., Delansorne R., Wakimoo N., Doan N.B., Akagi T., Shen M., et al. Inecalcitol, an analog of 1a,25(OH)2D3, induces growth arrest of androgen-dependent prostate cancer cells. International Journal of Cancer 2012, 130:2464-2473.
74. Palmer H.G., Gonzalex-Sancho J.M., Espada J., Berciano M.T., Puig I., Baulida J., et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling. The Journal of Cell Biology 2001, 154:369-387.
75. Patel D., Knowell A.E., Korang-Yeboah M., Sharma P., Joshi J., Glymph S., et al. Inhibitor of differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration-resistant prostate cancer. Molecular Endocrinology 2014, 28:1239-1253.
76. Perez-Stable C.M., Schwartz G.G., Farinas A., Finegold M., Binderup L., Howard G.A., et al. The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer: Target cells of carcinogenesis and the effect of the vitamin D analogue EB1089. Cancer Epidemiology, Biomarkers and Prevention 2002, 11:555-563.
77. Pike J.W., Lee S.M., Meyer M.B. Regulation of gene expression by 1,25-dihydroxyvitamin D3 in bone cells: Exploiting new approaches and defining new mechanisms. BoneKEy Reports 2014, 3:1-9. (article number: 482). 10.1038/bonekey.2013.216.
78. Rao A., Coan A., Welsh J.E., Barclay W.W., Koumenis C., Cramer S.D., et al. Receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Research 2004, 64:2143-2147.
79. Robson C.N., Gnanapragasam V., Byrne R.L., Cllins A.T., Neal D.E. Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. The Journal of Endocrinology 1999, 160:257-266.
80. Rohan J.N., Weigel N.L. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 2009, 150:2046-2054.
81. Rosenfeld M.G., Lunyak V.V., Glass C.K. Sensors and signals: A coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes & Development 2006, 20:1405-1428.
82. Saito T., Okamoto R., Haritunians T., O'Kelly J., Uskokovic M., Maehr H., et al. Novel Gemini-vitamin D3 analogs have potent antitumor activity. The Journal of Steroid Biochemistry and Molecular Biology 2008, 112:151-156.
83. Salehi-Tabara R., Nguyen-Yamamotoa L., Tavera-Mendoza L.E., Quail T., Dimitrov V., An B.S., et al. Vitamin D receptor as a master regulator of the c-MYC/MXD1 network. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:18827-18832.
84. Scher H.I., Buchanan G., Gerald W., Butlerand L.M., Tilley W.D. Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocrine-Related Cancer 2004, 11:459-476.
85. Seo Y.K., Mirkheshti N., Song C.S., Kim S., Dodds S., Ahn S.C., et al. SULT2B1b sulfotransferase: Induction by vitamin D receptor and reduced expression in prostate cancer. Molecular Endocrinology 2013, 27:925-939.
86. Sequeira V.B., Rybchyn M.S., Tongkao-on W., Gordon-Thomson C., Malloy P.J., Nemere I., et al. The role of the vitamin D receptor and ERp57 in photoprotection by 1α,25-dihydroxyvitamin D3. Molecular Endocrinology 2012, 26:574-582.
87. Sherr C.J., Roberts J.M. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes & Development 1999, 13:1501-1512.
88. Stewart L.V., Weigel N.L. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxy-vitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate 2005, 64:9-19.
89. Sung V., Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Molecular and Cellular Endocrinology 2000, 164:133-143.
90. Swami S., Krishnan A.V., Wang J.Y., Jensen K., Horst R., Albertelli A., et al. Dietary vitamin D and 1,25-dihydroxyvitamin D (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 2012, 153:2576-2587.
91. Tannour-Louet M., Lewis S.K., Louet J.F., Stewart J., Addai J.B., Sahin A., et al. Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D3-based therapies. FASEB Journal 2014, 28:364-372.
92. (waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Research 2011, 39(6):2045-2056.
93. Titus M.A., Schell M.J., Li F.B., Tomer K.B., Mohler J.L. Testosterone and dihydro-testosterone tissue levels in recurrent prostate cancer. Clinical Cancer Research 2005, 11:4653-4657.
94. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
95. Tuoresmäki P., Väisänen S., Neme A., Heikkinen S., Carlberg C. Patterns of genome-wide VDR locations. PLoS One 2014, 9(4):e96105.
96. Turunen M.M., Dunlop T.W., Carlberg C., Väisänen S. Selective use of multiple vitamin D response elements underlies the 1α, 25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene. Nucleic Acids Research 2007, 35:2734-2747.
97. VaÈisaÈnen S., PeraÈkylaÈ M., KaÈrkkaÈinen J.I., Steinmeyer A., Carlberg C. Critical role of helix 12 of the vitamin D3 receptor for the partial agonism of carboxylic ester antagonists. Journal of Molecular Biology 2002, 315:229-238.
98. Wang W.W., Chatterjee N., Chittur S.V., Welsh J., Tenniswood M.P. Effects of 1α, 25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Molecular Cancer 2011, 10:58.
99. Wang W.L., Tenniswood M. Vitamin D, intermediary metabolism and prostate cancer tumor progression. Frontiers in Physiology 2014, 5:1-9. (article number: 183). 10.3389/fphys.2014.00183.
100. Wang W.W., Welsh J., Tenniswood M. 1, 25 Dihydroxy vitamin D3 modulates lipid metabolism in prostate cancer cells through miRNA mediated regulation of PPARα. The Journal of Steroid Biochemistry and Molecular Biology 2013, 136:247-251.
101. 3: Metabolite structure, kinetics, inducibility, and interindividual variability. Endocrinology 2014, 155:2052-2063.
102. Washington M.N., Weigel N.L. 1α,25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology 2010, 151:1409-1417.
103. Watson L.C., Kuchenbecker K.M., Schiller B.J., Gross J.D., Pufall M.A., Yamamoto K.R. The glucocorticoid receptor dimer interface allosterically transmits sequence-specific DNA signals. Nature Structural and Molecular Biology 2013, 20:876-883.
104. Weigel N.L. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutrition Reviews 2007, 65:S116-S117.
105. Yang E.S., Burnstein K.L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. The Journal of Biological Chemistry 2003, 278:46862-46868.
106. Yang E.S., Maiorino C.A., Roos B.A., Knight S.R., Burnstein K.L. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Molecular and Cellular Endocrinology 2002, 186:69-79.
107. Yee S.W., Campbell M.J., Simons C. Inhibition of vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. The Journal of Steroid Biochemistry and Molecular Biology 2006, 98:228-235.
108. Zhan Q., Lord K.A., Alamo I., Hollander M.C., Carrier F., Ron D., et al. The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Molecular and Cellular Biology 1994, 14:2361-2371.
109. Zhang J., Chalmers M.J., Stayrook K.R., Burris L.L., Wang Y., Busby S.A., et al. DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. Nature Structural and Molecular Biology 2011, 18:556-563.
110. Zhao X.-Y., Peehl D.M., Navone N.M., Feldman D. 1α, 25-Dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 2000, 141:2548-2556.
111. Zhu J.G., Ochalek J.T., Kaufmann M., Jones G., DeLuca H.F. CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:15650-15655.
112. Zhuang S.-H., Burnstein K.L. Antiproliferative effect of 1α,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 1998, 139:1197-1207.